Gastroenteropancreatic neuroendocrine tumours.
Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mas...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1826260300705300480 |
|---|---|
| author | Modlin, I Oberg, K Chung, D Jensen, RT de Herder, W Thakker, R Caplin, M Delle Fave, G Kaltsas, G Krenning, E Moss, S Nilsson, O Rindi, G Salazar, R Ruszniewski, P Sundin, A |
| author_facet | Modlin, I Oberg, K Chung, D Jensen, RT de Herder, W Thakker, R Caplin, M Delle Fave, G Kaltsas, G Krenning, E Moss, S Nilsson, O Rindi, G Salazar, R Ruszniewski, P Sundin, A |
| author_sort | Modlin, I |
| collection | OXFORD |
| description | Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. Investigation and management should be highly individualised for a patient, taking into consideration the likely natural history of the tumour and general health of the patient. Management strategies include surgery for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoembolisation and radiofrequency ablation), chemotherapy, and somatostatin analogues to control symptoms that result from release of peptides and neuroamines. New biological agents and somatostatin-tagged radionuclides are under investigation. The complexity, heterogeneity, and rarity of GEP NETs have contributed to a paucity of relevant randomised trials and little or no survival increase over the past 30 years. To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling. More-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed. Comparison between treatments is currently very difficult. Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics. |
| first_indexed | 2024-03-06T19:03:27Z |
| format | Journal article |
| id | oxford-uuid:14529d57-6583-432d-b58d-3dc81a442a66 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:03:27Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:14529d57-6583-432d-b58d-3dc81a442a662022-03-26T10:19:02ZGastroenteropancreatic neuroendocrine tumours.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:14529d57-6583-432d-b58d-3dc81a442a66EnglishSymplectic Elements at Oxford2008Modlin, IOberg, KChung, DJensen, RTde Herder, WThakker, RCaplin, MDelle Fave, GKaltsas, GKrenning, EMoss, SNilsson, ORindi, GSalazar, RRuszniewski, PSundin, AGastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. Investigation and management should be highly individualised for a patient, taking into consideration the likely natural history of the tumour and general health of the patient. Management strategies include surgery for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoembolisation and radiofrequency ablation), chemotherapy, and somatostatin analogues to control symptoms that result from release of peptides and neuroamines. New biological agents and somatostatin-tagged radionuclides are under investigation. The complexity, heterogeneity, and rarity of GEP NETs have contributed to a paucity of relevant randomised trials and little or no survival increase over the past 30 years. To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling. More-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed. Comparison between treatments is currently very difficult. Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics. |
| spellingShingle | Modlin, I Oberg, K Chung, D Jensen, RT de Herder, W Thakker, R Caplin, M Delle Fave, G Kaltsas, G Krenning, E Moss, S Nilsson, O Rindi, G Salazar, R Ruszniewski, P Sundin, A Gastroenteropancreatic neuroendocrine tumours. |
| title | Gastroenteropancreatic neuroendocrine tumours. |
| title_full | Gastroenteropancreatic neuroendocrine tumours. |
| title_fullStr | Gastroenteropancreatic neuroendocrine tumours. |
| title_full_unstemmed | Gastroenteropancreatic neuroendocrine tumours. |
| title_short | Gastroenteropancreatic neuroendocrine tumours. |
| title_sort | gastroenteropancreatic neuroendocrine tumours |
| work_keys_str_mv | AT modlini gastroenteropancreaticneuroendocrinetumours AT obergk gastroenteropancreaticneuroendocrinetumours AT chungd gastroenteropancreaticneuroendocrinetumours AT jensenrt gastroenteropancreaticneuroendocrinetumours AT deherderw gastroenteropancreaticneuroendocrinetumours AT thakkerr gastroenteropancreaticneuroendocrinetumours AT caplinm gastroenteropancreaticneuroendocrinetumours AT dellefaveg gastroenteropancreaticneuroendocrinetumours AT kaltsasg gastroenteropancreaticneuroendocrinetumours AT krenninge gastroenteropancreaticneuroendocrinetumours AT mosss gastroenteropancreaticneuroendocrinetumours AT nilssono gastroenteropancreaticneuroendocrinetumours AT rindig gastroenteropancreaticneuroendocrinetumours AT salazarr gastroenteropancreaticneuroendocrinetumours AT ruszniewskip gastroenteropancreaticneuroendocrinetumours AT sundina gastroenteropancreaticneuroendocrinetumours |